Posledná aktualizácia :
19/11/2024
muskarínový antagonista   Scopolamine N-butyl bromide  
Injekcia
Stabilita roztokov Stabilita v zmesiach Faktory ovplyvňujúce stabilitu Kompatibility spôsob podania Odkazy na literatúru PDF
   Chemický vzorec  

Obchodný názov   Obchodný názov     

Obchodné názvy sú orientačné, a zloženie pomocných látok sa môže líšiť v závislosti od krajiny a výrobcu.

Buscapina Španielsko
Buscolysin Poľsko
Buscopan Austrália, Belgicko, Brazília, Egypt, Fínsko, Holandsko, Island, Kanada, Luxembursko, Nemecko, Nórsko, nový Zéland, Portugalsko, Rakúsko, Spojené arabské emiráty, Švajčiarsko, Švédsko, Tunisko, Turecko
Butilbromuro de hioscina Argentína, Kolumbia
Cifespasmo Argentína
Colobolina Argentína
Dolopina Ekvádor
Escopolamina N butyl bromuro Čile
Hiocin Venezuela
Hioscina Argentína, Kolumbia, peru
Hioscina butil bromuro Kolumbia, peru
Hyocidic Irán
Hyoscine Austrália
Hyoscine hydrobromide Kanada
Hyotex Irán
Pasmodina Drawer Argentína
Rupe N Argentína
Scoburen Francúzsko
Selpirans Venezuela
Spasmopan Tunisko
Xemol Turecko
Odkazy na literatúru   Injekcia   Odkazy na literatúru : Scopolamine N-butyl bromide  
Typ Publikácia
1230 Časopis Regnard C, Pashley S, Westrope F.
Anti-emetic / diamorphine mixture compatibility in infusion pumps.
Br J Pharm Pract 1986 ; 8: 218-220.
1232 Časopis Beatson C, Taylor A.
A physical compatibility study of furosemide & flucloxacillin injections.
Br J Pharm Pract 1987 ; 9: 223-226, 236.
1405 Časopis Peterson GM, Miller KA, Galloway JG, Dunne PF.
Compatibility and stability of fentanyl admixtures in polypropylene syringes.
J Clin Pharm Ther 1998 ; 23: 67-72.
1757 Časopis Schrijvers D, Tai-Apin C, De Smet MC, Cornil P, Vermorken JB, Bruyneel P.
Determination of compatibility and stability of drugs used in palliative care.
J Clin Pharm Ther 1998 ; 23: 311-314.
1847 Časopis Anacardo R, Perilli O, Bartolini S, Gentile MM, Mazzeo P, Carlucci G.
Physicochemical compatibility between ketoprofen kysine salt injections (Artrosilene®) and pharmaceutical products frequently used for combined therapy by intravenous administration.
J Pharm Biomed Anal 2003 ; 32, 6: 1235-1241.
1966 Časopis Barcia E, Reyes R, Azuara L, Sànchez Y, Negro S.
Stability and compatibility of binary mixtures of morphine hydrochloride with hyoscine-n-butyl bromide.
Support Care Cancer 2005 ; 13, 4: 239-245.
1970 Časopis Barcia E, Reyes R, Azuara M.L, S?nchez Y, Negro S.
Compatibility of haloperidol and hyoscine-N-butyl bromide in mixtures for subcutaneous infusion to cancer patients in palliative care.
Support Care Cancer 2003 ; 11, 2: 107-113.
1971 Časopis Azuara ML, Sanchez Y, Reyes R, Barcia E.
Physical compatibility and in vivo evaluation of drug mixtures forsubcutaneous infusion to cancer patients in palliative care.
Support Care Cancer 2001
2055 Časopis Negro S, Reyes R, Azuara ML, Sanchez Y, Barcia E.
Morphine, haloperidol and hyoscine N-butyl bromide combined in sc infusion solutions : compatibility and stability evaluation in terminal oncology patients.
Int J Pharm 2006 ; 307: 278-284.
2125 Časopis Gardiner PR.
Compatibility of an injectable oxycodone formulation with typical diluents, syringes, tubings, infusion bags and drugs for potential co-administration.
Hospital Pharmacist 2003 ; 10: 354-361.
2176 Časopis Barcia E, Martin A, Azuara ML, Sanchez Y, Negro S.
Tramadol and hyoscine N-butyl bromide combined in infusion solutions: compatibility and stability.
Support Care Cancer 2007 ; 15: 57-62.
2900 Časopis Hines S, Pleasance S.
Compatibility of an injectable high strength oxycodone formulation with typical diluents, syringes, tubings,infusion bags and drugs for potential co-administration.
EJHP 2009 ; 15, 5: 32-38.
3132 Časopis Negro S, Martin A, Azuara L, Sanchez Y, Barcia E.
Compatibility and stability of ternary admixtures of tramadol, haloperidol, and hyoscine.
J Palliat Med 2010 ; 13, 3: 273-277.
4404 Poster Müller U, Haller F, Wiedemeier P, Steuer C.
Compatibility studies of seven commonly used drugs for parenteral administration in palliative care.
JFSPH 2019 2019

  Mentions Légales